These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1349 related items for PubMed ID: 18049330

  • 1. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [Abstract] [Full Text] [Related]

  • 2. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR.
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [Abstract] [Full Text] [Related]

  • 3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 4. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
    Song S, Wang Y, Zhang Y, Wang F, He Y, Ren D, Guo Y, Sun S.
    Cancer Lett; 2007 Oct 18; 256(1):90-100. PubMed ID: 17656012
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T, Kamigaki T, Nakamura T, Imanishi T, Hayashi S, Kawasaki K, Takase S, Ajiki T, Kuroda Y.
    Oncol Rep; 2006 Dec 18; 16(6):1317-24. PubMed ID: 17089056
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.
    Cancer Res; 2004 Jul 15; 64(14):4973-9. PubMed ID: 15256471
    [Abstract] [Full Text] [Related]

  • 7. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Int Immunol; 2006 Mar 15; 18(3):425-34. PubMed ID: 16415100
    [Abstract] [Full Text] [Related]

  • 8. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z, Fan H, Wu Y, Chen B.
    Cytotherapy; 2005 Mar 15; 7(4):353-62. PubMed ID: 16162457
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.
    Clin Immunol; 2009 Nov 15; 133(2):184-97. PubMed ID: 19664962
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y, Huang H, Chen Z, Zong L, Xiang J.
    J Gene Med; 2003 Aug 15; 5(8):668-80. PubMed ID: 12898636
    [Abstract] [Full Text] [Related]

  • 11. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Cancer Res; 2001 Oct 15; 61(20):7563-7. PubMed ID: 11606395
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA.
    Clin Cancer Res; 2005 Feb 01; 11(3):1302-11. PubMed ID: 15709202
    [Abstract] [Full Text] [Related]

  • 13. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I.
    Vaccine; 2006 Mar 10; 24(11):1880-8. PubMed ID: 16300869
    [Abstract] [Full Text] [Related]

  • 14. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
    Cho HI, Kim EK, Park SY, Lee SK, Hong YK, Kim TG.
    Cancer Lett; 2007 Dec 18; 258(2):189-98. PubMed ID: 17931768
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.
    Kim HS, Choo YS, Koo T, Bang S, Oh TY, Wen J, Song SY.
    Immunol Lett; 2006 Mar 15; 103(2):142-8. PubMed ID: 16313973
    [Abstract] [Full Text] [Related]

  • 16. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.
    J Immunother; 2008 Jan 15; 31(1):101-12. PubMed ID: 18157017
    [Abstract] [Full Text] [Related]

  • 17. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC, Lin P, Zhang J, Lu YR, Ning QZ, Wang Q.
    Tissue Antigens; 2006 May 15; 67(5):368-76. PubMed ID: 16671943
    [Abstract] [Full Text] [Related]

  • 18. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY, Yang JY, Dou KF, Ma LY, Teng ZH.
    Hum Immunol; 2007 May 15; 68(5):334-41. PubMed ID: 17462500
    [Abstract] [Full Text] [Related]

  • 19. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP, Weng YS, Wu QQ.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep 15; 28(9):646-9. PubMed ID: 17274366
    [Abstract] [Full Text] [Related]

  • 20. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z, Huang H, Chang T, Carlsen S, Saxena A, Marr R, Xing Z, Xiang J.
    Cancer Gene Ther; 2002 Sep 15; 9(9):778-86. PubMed ID: 12189528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.